BMS 986166
Alternative Names: BMS-986166; BMS-986166-04; S1PR1 modulatorLatest Information Update: 28 Mar 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Amines; Anti-inflammatories; Antirheumatics; Antiulcers; Cyclopentanes; Naphthalenes; Neuroprotectants; Phenyl ethers; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- No development reported Encephalitis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Encephalitis in USA (PO)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
- 22 Aug 2022 Bristol-Myers Squibb completes a phase II trial in Atopic dermatitis in USA, Spain, Poland, Germany, Canada, Austria and Australia (PO) (NCT05014438) (EudraCT2020-004767-77)